Tarsus Pharmaceuticals, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. (ticker: TARS) is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States, with headquarters in Irvine, California. Founded in November 2016, the company was built around a focused strategy in ophthalmology and infectious-disease adjacent therapeutics, aiming to identify and commercialize differentiated products in underserved, high-unmet-need markets. For international investors, Tarsus is best viewed as a specialty-healthcare growth story rather than a diversified large-cap pharmaceutical group. The company’s core value driver is XDEMVY® (lotilaner ophthalmic solution) 0.25%, which received FDA approval in the United States in July 2023 for the treatment of Demodex blepharitis and was launched commercially in August 2023. That approval marked a major inflection point, shifting Tarsus from a development-stage biotech into a commercial-stage company focused on market education, patient access, payer coverage, and adoption among eye-care professionals. In practical terms, the company’s operating model now revolves around building awareness of the disease, driving prescriptions, and scaling a specialized ophthalmology sales effort across the U.S. From a competitive standpoint, Tarsus holds an important first-mover position in Demodex blepharitis, a condition that has historically been underdiagnosed and under-treated. This gives the company a meaningful commercial opportunity if it can continue converting awareness into sustained prescription demand. At the same time, the business remains concentrated in a single lead asset, which means execution risk, reimbursement dynamics, and the pace of physician adoption are all critical variables for investors to monitor. Beyond the U.S. franchise, Tarsus has an international dimension through licensing and development partnerships. Its China-related regulatory pathway, advanced with partner Grand Pharmaceutical Group, provides an additional option for value creation outside the domestic market. The company has also signaled pipeline ambitions beyond XDEMVY, including work on a potential oral prophylactic approach for Lyme disease prevention, suggesting a broader long-term platform strategy. Recent business highlights reinforce the commercial momentum. In 2026, Tarsus reported continued growth and reaffirmed its full-year 2026 guidance for XDEMVY net product sales of $670–700 million, while also stating a peak sales potential above $2 billion. It has also continued to expand its commercial footprint and investor messaging around deeper penetration in eye-care practices. Overall, TARS is a U.S. NASDAQ-listed specialty pharma company with a compelling single-product launch story, a clear U.S. commercial focus, and emerging pipeline and international upside that could broaden the investment case over time.